Skip to main content

Articles

Alunbrig, an Oral Kinase Inhibitor, Receives FDA Approval for NSCLC with ALK Mutation

Rydapt First Drug in Decades Approved by the FDA for Acute Myeloid Leukemia

Stivarga First Drug in a Decade Approved by the FDA for Liver Cancer

Atezolizumab Approved as First-Line Treatment for Advanced Bladder Cancer in Some Patients

Bavencio, a PD-L1 Inhibitor, First Nonchemotherapy Drug Approved for Merkel-Cell Carcinoma

Neratinib First Extended Adjuvant Treatment for Patients with Early-Stage, HER2-Positive Breast Cancer

Blincyto Receives Expanded Indication to Include Patients with Ph+ B-Cell Precursor ALL

Kevzara (Sarilumab): A Novel IL-6 Receptor Antagonist for Rheumatoid Arthritis

Practice Management

Emphasize Shared Decision-Making Between Physicians and Patients to Improve Diabetes Outcomes

Gary Branning, MBA; Stacey L. Worthy, Esq; and Martha Vater

Practice Management

Value Frameworks in Oncology: Comparative Analysis and Implications to the Pharmaceutical Industry

Mark Slomiany, PhD, MBA, MPA; Priya Madhavan; Michael Kuehn; Sasha Richardson, MBA

Stakeholder Perspective

Payers’ Utilization of Value Frameworks Tools in Their Drug Coverage Decision-Making

Matthew Mitchell, PharmD, MBA, FAMCP

Page 86 of 245
Results 851 - 860 of 2441